November 18, 2013
Pharmacosmos to join the 9th Congress of ECCO
Inflammatory Bowel Diseases 2014 in Copenhagen.
Pharmacosmos will join the 9th Congress of ECCO Inflammatory
Bowel Diseases 2014, to be held in Copenhagen February 20-22,
Pharmacosmos will participate with a booth and will also be
hosting a satellite symposium entitled "Optimising iron treatment
for IBD patients - NEW clinical data and a NEW e-tool," on Thursday
20th. February at 11:30 am.
ECCO is the European Crohn's and Colitis Organisation and
the congress is the major European educational event in the field
of Inflammatory Bowel Diseases (IBD) and has achieved large
popularity across the world.
ECCO 2014 in Copenhagen will provide a unique opportunity
to gain access to the latest and best scientific information and
education in adult and paediatric gastroenterology, hepatobiliary
disease, endoscopy, imaging, gastrointestinal surgery related to
The congress aims are to advance the understanding of
digestive disorders, to improve the development of guidelines
through the most robust process, to define better and valid
outcomes for the therapy of IBD, all to enhance patient care. By
promoting research, integrating basic science and clinical
practice, fostering international collaboration and friendship, IBD
experts strive to bring hope and comfort to the many people who
suffer from IBD.
Please visit www.ecco-ibd.eu/ecco14
for further information.
About Pharmacosmos A/S
Headquartered in Denmark, Pharmacosmos is a family-owned,
international healthcare company with more than 50 years of
innovation and leadership in iron- and carbohydrate-based
treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses
on improving the lives of patients with iron deficiency with or
without anaemia. More than 1 billion people live with iron
deficiency anaemia and it is the leading cause of death for an
estimated 180,000 people every year. This makes it one of the
largest global health challenges of our time.
Pharmacosmos has subsidiaries in the Nordics, the UK and the US
and its products are marketed in more than 80 countries across the
world. Its manufacturing facilities are approved, among others, by
the Danish Medicines Agency and the US FDA.